SciSparc Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SPRC research report →
Price Chart
About the company
SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules. Their therapeutic pipeline encompasses several key drug candidates: SCI-110, which is being investigated for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease; SCI-160, designed to address pain; and SCI-210, targeting autism spectrum disorder and epilepsy.
- CEO
- Oz Adler
- IPO
- 2021
- Employees
- 3
- HQ
- Tel Aviv, TA, IL
Get TickerSpark's AI analysis on SPRC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $250.44K
- P/E
- -0.02
- PEG
- 0.00
- P/S
- 0.29
- P/B
- 0.04
- EV/EBITDA
- 0.47
- Div Yield
- 0.00%
- Gross Margin
- 46.38%
- Op Margin
- -1022.08%
- Net Margin
- -1422.78%
- ROE
- -704.60%
- ROIC
- -152.55%
Latest fiscal year · YoY change
- Revenue
- $856.00K-34.5%
- Gross Profit
- $631.00K+24.7%
- Op Income
- $-8,749,000
- Net Income
- $-12,179,000-93.8%
- EPS
- $-882.64-8980.7%
- OCF Growth
- +18.9%
- FCF Growth
- +18.9%
- 52W High
- $43.65
- 52W Low
- $2.98
- 50D MA
- $5.89
- 200D MA
- $6.58
- Beta
- 2.44
- RSI (14)
- 36
- Avg Volume
- 183.22K
No earnings-call transcripts are available for SPRC yet.
- Free Float
- 99.9%
- Shares Outstanding
- 57.84K
- Float Shares
- 57.80K
of shares held by institutions
3 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Hrt Financial LP | 21.23K | ▲ 21.23K |
| Jane Street Group, LLC | 16.50K | ▲ 16.50K |
| Citadel Advisors LLC | 11.06K | ▲ 11.06K |
| Ubs Group AG | 4.52K | ▲ 1.37K |
| Jpmorgan Chase & Co | 211 | ▲ 211 |
| Morgan Stanley | 200 | ▲ 200 |
| Sbi Securities Co., Ltd. | 12 | ▲ 11 |
Held by 7 ETFs
Biggest fund positions in SPRC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 3, 22 | Adler Oz | other | 6 |
| Mar 18, 26 | Revach Moshe | other | 0 |
| Jan 3, 22 | Revach Moshe | other | 1 |
| Mar 18, 26 | Shay Amnon Ben | other | 0 |
| Jan 3, 22 | Shay Amnon Ben | other | 1 |
| Mar 18, 26 | DAYAN ALON | other | 0 |
| Jan 3, 22 | DAYAN ALON | other | 1 |
| Mar 18, 26 | Sidi Liat | other | 0 |
| Jan 3, 22 | Sidi Liat | other | 1 |
| Jan 3, 22 | Weiss Amitay | other | 6 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SPRC coverage
Recent articles, reports, and earnings notes.
No research on SPRC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SPRC report →SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
globenewswire.com · Sep 23
SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
thenewswire.com · Sep 2
SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
thenewswire.com · Sep 2
SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial
globenewswire.com · Aug 31
NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial
thenewswire.com · Aug 31
Neurothera Labs Inc. Announces Share Consolidation
thenewswire.com · Aug 28
NeuroThera Labs Engages Dr. Reuter Investor Relations
thenewswire.com · Aug 27
SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board
globenewswire.com · Aug 26
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.